# A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants

> **NCT01780259** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 58 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Esketamine
- **DRUG:** Placebo
- **DRUG:** Triazolam

## Key facts

- **NCT ID:** NCT01780259
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2013-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01780259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01780259, "A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01780259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*